Please assess the completion status of the following clinical trial:

Trial Title: Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained according to international guidelines and local law;~2. Male or female patients aged \> 60 years without upper age limit;~3. Patients with primary or secondary AML according to WHO (≥ 20% blasts in the peripheral blood (pB) or bone marrow (BM)) who are not expected to benefit from standard remission-induction chemotherapy;~4. Patients with \< 30 000 leukocytes/μl;~5. Performance status ECOG 0, 1, 2;~6. Creatinine \< 2.0 mg/dl (unless leukemia-related);~7. Ability to understand the nature of the study and the study related procedures and to comply with them.~Exclusion Criteria:~1. AML of FAB subtype M3;~2. Previous remission-induction chemotherapy for MDS or AML, previous allografting;~3. Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA;~4. Low-dose chemotherapy (e.g. hydroxyurea, cytosine arabinoside (Ara-C), melphalan, clofarabine etc.) within 4 weeks prior to DAC treatment, except for cytoreduction of leukocytosis ≥ 30 000/μl with hydroxyurea or Ara-C as proscribed by the study protocol (section 7.3 and 7.4); the patient must have recovered from all clinically relevant reversible non-hematologic toxicities;~5. Treatment with tyrosine kinase inhibitors, immunomodulating agents (IMIDS) or other investigational AML treatment within the last 4 weeks or in a time period of drug half-life x 5 (whatever is shorter) before the first administration of DAC;~6. Treatment with cytokines within previous 4 weeks;~7. Concomitant therapy which is considered relevant for the evaluation of efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy);~8. Other malignancy requiring treatment (previous chemotherapy for other malignancies is not an exclusion criteria);~9. Cardiac insufficiency NYHA IV;~10. Insufficient hepatic function (bilirubin, AST or ALT \> = 2.5 x Upper Limit of Normal (ULN)) (unless leukemia-related);~11. Fatal hepatic function disorder during treatment with valproic acid in siblings;~12. Hepatic porphyria;~13. Manifest serious pancreatic function disorder;~14. Plasmatic coagulation disorder not related to AML;~15. Known active hepatitis B or C;~16. Known HIV infection;~17. Other uncontrolled active infections;~18. Known allergy against soy beans or peanuts;~19. Psychiatric disorder that interferes with treatment;~20. Patient without legal capacity who is unable to understand the nature, significance and consequences of the study;~21. Known hypersensitivity to, or intolerance of, one of the trial drugs, another retinoid or the excipients of the trial drugs;~22. Concomitant use of any other investigational drug or participation in a clinical trial within the last thirty days before the start of this study; simultaneous participation in registry and diagnostic trials is allowed;~23. Female patients who are pregnant or breast feeding;~24. Fertile patients refusing to use safe contraceptive methods during the study (for details see clinical trial protocol section 5.3);~25. Known or persistent abuse of medication, drugs or alcohol.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
- Decitabine+VPA (Type: EXPERIMENTAL): i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
- Decitabine+ATRA (Type: EXPERIMENTAL): i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
- Decitabine+VPA+ATRA (Type: EXPERIMENTAL): i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).